Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company based in Newark, California, that discovers and develops peptide-based therapeutics. Its lead candidate, rusfertide, is an injectable hepcidin mimetic being developed for polycythemia vera and other iron overload disorders. The company also developed icotrokinra (formerly PN-235), an oral IL-23 receptor antagonist peptide for inflammatory diseases such as psoriasis, which is partnered with Johnson & Johnson. Protagonist's pipeline has historically spanned inflammation and immunology, hematology, and metabolic diseases, with additional programs targeting IL-17 and iron metabolism. The company generates collaboration revenue through licensing and development agreements, notably with Janssen Biotech (Johnson & Johnson) and Takeda, while advancing its own wholly owned candidates. Its operations are primarily in the United States, with clinical trials conducted internationally.

Piotroski F-Score

Interest Coverage

Beneish M-Score

Financial Strength

Altman Z-Score

Tax Rate

Asset Growth

Insider Sell

PB Ratio

PE Ratio

Price